Continuous administration of low-dose tegafur-uracil (UFT) for 2 years after curative concurrent chemoradiotherapy (CCRT) did not improve median progression-free survival (PFS) or median overall survival (OS), results of the GOTIC-002 LUFT trial demonstrated.
The current standard therapy for locally advanced cervical cancer (LACC) is CCRT followed by brachytherapy. However, there is room to improve survival, e.g. by giving maintenance chemotherapy after CCRT. Maintenance with UFT improves survival in gastric, lung, colon, and breast cancer [1–5]. The GOTIC-002 LUFT trial (jRCTs031180174) evaluated the efficacy and safety of low-dose UFT for 2 years as maintenance chemotherapy after curative CCRT for patients with LACC. Prof. Keiichi Fujiwara (Saitama Medical University, Japan) presented the results .
During 8 years, the study enrolled 351 patients with LACC (FIGO 1B2-IVa) with a partial or complete response after curative CCRT. Participants were 1:1 randomised to maintenance UFT (300 mg or 400 mg every day for 2 years) or observation. The primary endpoint was PFS; secondary endpoints included OS, safety and quality-of-life.
Maintenance UFT did not improve median PFS over observation (62.0% vs 61.3%; HR 0.92; P=0.634) or median OS (76.1% vs 77.6%; HR 1.04; P=0.869). Maintenance UFT was well tolerated, with grade ≥3 adverse events observed in 22.6% of participants in the UFT arm compared with 15.9% of observed participants).
Based on these results, Prof. Fujiwara acknowledged that “continuous administration of low-dose UFT for 2 years after curative CCRT does not improve PFS or OS.”
- Nakajima T, et al. Br J Surg. 2007;94(12):1468–1476.
- Kato H, et al. N Engl J Med. 2004;350(17):1713–1721.
- Akasu T, et al. Jpn J CLin Oncol. 2006;36(4):237–2344.
- Kasumi F, et al. Oncology. 2003;64(2):146–153.
- Fujiwara K, et al. Randomized phase III trial of maintenance chemotherapy with tegafur-uracil versus observation following concurrent chemoradiotherapy for locally advanced cervical cancer, GOTIC-002 LUFT trial. Abstract LBA31, ESMO Congress 2022, 09–13 September, Paris, France.
Copyright ©2022 Medicom Medical Publishers
« Adjuvant nivolumab plus ipilimumab does not improve survival in patients with localised RCC at high risk of relapse after nephrectomy Next Article
OS benefit for advanced ovarian cancer patients treated with maintenance olaparib »
Table of Contents: ESMO 2022
Letter from the Editor
High pathological responses to neoadjuvant immune checkpoint inhibition in locally advanced dMMR colon cancer
Fruquintinib: a potential new treatment for patients with refractory mCRC
Second-line avelumab is effective in patients with MSI-H/dMMR mCRC
Upper Gastrointestinal Cancer
Deep learning models predict the risk of relapse and the mutational profile in GIST
Addition of pembrolizumab to lenvatinib does not improve OS in advanced HCC
New, highly selective inhibitor of FGFR2 driver alterations and resistance mutations
Chemo-immunotherapy in gastric cancer is more effective when administered in parallel
Tumour infiltrating lymphocytes identify patients with immunogenic triple-negative breast cancer
OS benefit of abemaciclib in HR-positive/HER2-negative advanced breast cancer not (yet) statistically significant
OS benefit of sacituzumab govitecan in pre-treated HR-positive/HER2-negative metastatic breast cancer
A pathway from air pollution to lung cancer in non-smokers identified
Selective KRASG12C inhibitor sotorasib demonstrates superior PFS and ORR compared to docetaxel in previously treated patients with NSCLC
Promising clinical activity of tepotinib plus osimertinib in NSCLC with MET amplification after progression on first-line osimertinib
High pathological responses in borderline resectable NSCLC patients after induction with dual immunotherapy and concurrent chemoradiotherapy
Treatment with tumour-infiltrating lymphocytes for advanced melanoma outperforms ipilimumab
Neoadjuvant pembrolizumab outperforms adjuvant pembrolizumab in resectable stage III–IV melanomas
Survival-benefit of neoadjuvant T-VEC maintained over 5 years of follow-up
Baseline ctDNA predicts survival in resected stage III–IV melanoma
Genitourinary Cancer – Prostate Cancer
Overall survival benefit of abiraterone in mHSPC is maintained for 7 years
Limited benefit of adding long-term ADT to post-operative radiotherapy in prostate cancer
Intensified ADT benefits biochemical progression-free survival in biochemically relapsed prostate cancer
Genitourinary Cancer – Non-Prostate Cancer
Adjuvant nivolumab plus ipilimumab does not improve survival in patients with localised RCC at high risk of relapse after nephrectomy
Triple therapy improves progression-free survival in patients with advanced RCC versus dual therapy
Adjuvant atezolizumab does not improve outcomes for patients with RCC and increased risk of recurrence
OS benefit for advanced ovarian cancer patients treated with maintenance olaparib
Maintenance tegafur-uracil does not improve survival in locally advanced cervical cancer
Head and Neck Cancer
Adding first-line pembrolizumab to CRT in locally advanced HNSCC does not significantly prolong survival or event-free survival
5-FU-free chemotherapy combination as an alternative for first-line treatment of recurrent or metastatic HNSCC
Epstein Barr virus-specific autologous cytotoxic T lymphocytes do not improve survival in nasopharyngeal carcinoma